What is Blood Cancer and treatment for blood cancer
Leukemia or Blood Cancer is actually a group of different cancers of the blood cells. Leukemia can be acute or chronic, and people with chronic leukemia’s may not notice any symptoms before the condition is diagnosed with a blood test. Acute leukemia’s are more likely to cause symptoms. Symptoms of all forms of leukemia are related to the proliferation of abnormal blood cells and replacement of the bone marrow by the cancerous cells.
- Leukemia’s are grouped by how quickly the disease develops (acute or chronic) as well as by the type of blood cell that is affected (lymphocytes or myelocytes). The four main types of leukemia include acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML), and chronic myelocytic leukemia (CML).
- People with leukemia are at significantly increased the risk for developing infections, anemia, and bleeding. Other symptoms and signs include easy bruising, weight loss, night sweats, and unexplained fevers.
- The diagnosis of leukemia is supported by findings of the medical history and examination, and examining blood and bone marrow samples under a microscope.
Treatment for Leukemia
- As our focus is on the biology of the cancers and their treatments, we do not give detailed treatment guidelines. Instead, we link to organisations in the U.S. that generate the treatment guidelines.
The National Cancer Institute lists the following treatments for leukemia:
- Radiation Therapy
- Stem Cell Transplantation
- Treatment of leukemia depends on the type of leukemia, certain features of the
Leukemia cells, the extent of the disease, and prior history of treatment, as well as the age and health of the patient.
- Most patients with leukemia are treated with chemotherapy. Some patients also may have radiation therapy and/or bone marrow transplantation.
- The diagnostic and treatment market for hematological cancers, which are cancer of the blood, bone marrow, and lymphatic systems, should near approach double-digit growth. In males, leukemia is the ninth most common blood cancer. The market was dominated by treatments for chronic myeloid leukemia (CML) in 2012. The growing population of individuals suffering from leukemia is growing this market, along with novel drugs that offer improved efficacy. Leukemia remains a treatment area that has the high unmet need for early diagnosis, with limited treatment options.
- In the market instruments, competition involves several factors, including price, product innovation, product demand, and service, distribution, sales and promotion strategies. A number of patients prefer home monitoring devices, which have led to a decline in demand for stand-alone coagulation analyzers, and therefore low-volume analyzers continue to be replaced by home monitoring devices. Near patient testing, blood-thinning therapeutics, and clot removal techniques continue to drive the market for the coagulation analyzers.
- Sustaining competitive advantage will require significant investment in research and product innovations, along with strategic alliances. The market should grow and see increased competition due to innovative product launches by new companies.